[oxLDL/β2GPI/anti-β2GPI antibody complex inhibits autophagy in RAW264.7 cells through the activation of AKT pathway].

Objective To investigate the effect of oxidative low-density lipoprotein/β2 glycoprotein I/anti-β2 glycoprotein I antibody (oxLDL/β2GPI/anti-β2GPI antibody) complex on autophagy in mouse macrophages (RAW264.7 cells) and its mechanism. Methods RAW264.7 cells were stimulated with medium, oxLDL, oxLDL/β2GPI complex, oxLDL/β2GPI/anti-β2GPI antibody complex, oxLDL/anti-β2GPI antibody complex and β2GPI/anti-β2GPI antibody complex separately. The protein levels of autophagy-associated proteins including LC3 and P62 were detected by Western blot analysis. The tandem mRFP-GFP-LC3 adernovirus was used to detect the patency of autophagosomes and autophagy flow. The AKT pathway inhibitor LY294002 (50 μmol/L) was used for investigating the role of AKT pathway in the autophagy in RAW264.7 cells treated by oxLDL/β2GPI/anti-β2GPI antibody complex. Results oxLDL/β2GPI/anti-β2GPI antibody complex reduced the level of LC3-II protein and the number of autophagosomes, increased the level of P62 protein and blocked the autophagy flow. In addition, the autophagy in RAW264.7 cells was partially restored by the pre-treatment of LY294002. Conclusion The oxLDL/β2GPI/anti-β2GPI antibody complex can inhibit the autophagy in RAW264.7 cells through activating the AKT pathway.